Morphic Holding stock was surging Monday after pharmaceutical giant Eli Lilly agreed to acquire the biopharmaceutical company in a $3.2 billion deal. Lilly has agreed to pay $57 a share for ...

The American pharmaceutical company Eli Lilly & Co. has entered into an agreement to acquire the biopharmaceutical company Morphic Holding Inc. This is reported in a press release Eli Lilly. The ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

The maintained Buy rating and price target signal confidence in Eli Lilly's continued growth and ... The company has also completed the acquisition of Morphic Holding (NASDAQ:MORF), Inc., adding ...

Eli Lilly and Company announced the successful completion of its acquisition of Morphic Holding, Inc. Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious ...

Eli Lilly is acquisitive, too, and just purchased a company called Morphic Holding ... Eli Lilly looks like a great stock to buy and hold for the long run, while its top-notch track record ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from TD Cowen maintained a Buy rating on the stock and ...

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

After a period of rating suspensions, Citi resumed its coverage on Eli Lilly (NYSE:LLY) with a buy recommendation and a $1,060 price target, citing the company’s GLP-1 pipeline, including its ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut ...